COPD Clinical Trial
Official title:
The JADE Study: A 12-week, Double-blind, Randomized Study to Investigate the Effect of 500 mcg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease
Verified date | September 2016 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | Malaysia: Ministry of Health |
Study type | Interventional |
The aim of the study is to compare the effect of roflumilast on lung function in patients with COPD. Roflumilast will be administered orally once daily in the morning at one dose level. The study duration consists of a baseline period (4 weeks) and a treatment period (12 weeks). The study will provide further data on safety and tolerability of roflumilast.
Status | Completed |
Enrollment | 551 |
Est. completion date | August 2007 |
Est. primary completion date | May 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Main Inclusion Criteria: - Written informed consent - Patients with a history of chronic obstructive pulmonary disease (COPD) as defined by the GOLD criteria (2003) - FEV1/FVC ratio (post bronchodilator) smaller or equal 70% - FEV1 (post bronchodilator) 30-80% of predicted - Fixed airway obstruction - Current smoker or former smoker (smoking cessation at least one year ago) with a smoking history of at least 10 pack years - Clinically stable COPD within 4 weeks prior to baseline visit - Availability of a chest x-ray Main Exclusion Criteria: - COPD exacerbation indicated by a treatment with systemic glucocorticosteroids - Lower respiratory tract infection - Diagnosis of asthma - Known alpha-1-antitrypsin deficiency - Need for long term oxygen therapy defined as longer or equal 16 hours/day - Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation (as assessed by the investigator) - Known infection with HIV, active hepatitis and/or liver insufficiency (according to the Child Pugh score A or worse) - Diagnosis or history of cancer - Clinically significant cardiopulmonary abnormalities - Pregnancy, breast feeding, oocyte donation or oocyte implantation planned during the trial - Female patients of childbearing potential, not using reliable method of contraception for the entire study duration, post-menopausal > 1 year or who are not using any other method considered sufficiently reliable by the investigator in individual cases - Participation in another study (use of investigational product) within 30 days preceding the baseline visit or re-entry of patients already enroled in this trial - Alcohol or drug abuse - Inability to follow the study procedures due to e.g., language problems, physiological disorders - Use of not allowed drugs - Suspected hypersensitivity to the study medication or rescue medication |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Hong Kong | Altana Pharma/Nycomed | Hong Kong | |
Hong Kong | Altana Pharma/Nycomed | Shatin, NT, Hong Kong | |
Korea, Republic of | Altana Pharma/Nycomed | Anvang-Si, Gveonggi-Do | |
Korea, Republic of | Altana Pharma/Nycomed | Chungbuk | |
Korea, Republic of | Altana Pharma/Nycomed | Gangwon-do | |
Korea, Republic of | Altana Pharma/Nycomed | Gangwon-Do | |
Korea, Republic of | Altana Pharma/Nycomed | Gwangju | |
Korea, Republic of | Altana Pharma/Nycomed | Gyeonggi-do | |
Korea, Republic of | Altana Pharma/Nycomed | Jiniu-Si. Gveongsangnam-Do | |
Korea, Republic of | Altana Pharma/Nycomed | Seoul | |
Korea, Republic of | Altana Pharma/Nycomed | Seoul | |
Korea, Republic of | Altana Pharma/Nycomed | Seoul | |
Korea, Republic of | Altana Pharma/Nycomed | Seoul | |
Korea, Republic of | Altana Pharma/Nycomed | Seoul | |
Korea, Republic of | Altana Pharma/Nycomed | Seoul | |
Korea, Republic of | Altana Pharma/Nycomed | Uijongbu-city, Gveonggi-Do | |
Korea, Republic of | Altana Pharma/Nycomed | Ulsan | |
Malaysia | Altana Pharma/Nycomed | Jalan Rasah, Seremban | |
Malaysia | Altana Pharma/Nycomed | Kota Bharu / Kelantan | |
Malaysia | Altana Pharma/Nycomed | Kota Kinabalu, Sabah | |
Malaysia | Altana Pharma/Nycomed | Kuala Lumpur | |
Malaysia | Altana Pharma/Nycomed | Kuala Lumpur | |
Malaysia | Altana Pharma/Nycomed | Kuala Lumpur | |
Philippines | Altana Pharma/Nycomed | Manila | |
Philippines | Altana Pharma/Nycomed | Quezon City | |
Philippines | Altana Pharma/Nycomed | Quezon City | |
Philippines | Altana Pharma/Nycomed | Quezon City | |
Philippines | Altana Pharma/Nycomed | Quezon City | |
Taiwan | Altana Pharma/Nycomed | Kaohsiung | |
Taiwan | Altana Pharma/Nycomed | Taipei | |
Taiwan | Altana Pharma/Nycomed | Taipei | |
Taiwan | Altana Pharma/Nycomed | Taipei City 114 | |
Taiwan | Altana Pharma/Nycomed | Tau-Yuan |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Hong Kong, Korea, Republic of, Malaysia, Philippines, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | mean change from randomization to endpoint in lung function (post bronchodilator) | 12 weeks | No | |
Secondary | mean change from randomization to endpoint in pre and post bronchodilator spirometric parameters | 12 weeks | No | |
Secondary | exacerbation rate | 12 weeks | No | |
Secondary | adverse events | 12 weeks | Yes | |
Secondary | changes in laboratory values | 12 weeks | Yes | |
Secondary | changes in vital signs | 12 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04105075 -
COPD in Obese Patients
|
||
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |